Find a Doctor
Sepideh Mokhtari, MD
Locations: Moffitt Cancer Center
Cancer Focus: Brain Cancer , Glioblastoma , Meningioma , Neurofibromatosis
Dr. Sepideh Mokhtari is an Assistant Member in the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Mokhtari received her medical degree from Texas A&M College of Medicine in Temple, TX. She completed a Neurology Residency at Houston Methodist Hospital, where she also served as Chief Resident. She most recently completed a Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Mokhtari’s clinical interests are primarily in brain tumors and neurologic complications of cancer. Her research focus is neurologic complications of immunotherapy and paraneoplastic syndromes. In addition, her research interests include patients with neurofibromatosis with plexiform neurofibromas, meningiomas, acoustic neuromas and ependymomas. She is the director of Tuberous Sclerosis clinic and co-director of Neurofibromatosis clinic at Moffitt Cancer Center.
Education & Training
- Memorial Sloan Kettering Cancer Center - Neuro-Oncology
- Houston Methodist Hospital - Neurology
- Texas A&M(MD, - MD)
CLINICAL TRIAL 20247
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Condition: Neurologic Oncology
- Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
- Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol. 2019 Dec.267(4):1023-1025. Pubmedid: 31832829.
- B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
- Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.